Review:
Environmental Impact Assessment In Pharmaceuticals
overall review score: 3.8
⭐⭐⭐⭐
score is between 0 and 5
Environmental Impact Assessment in Pharmaceuticals (EIA-P) is a comprehensive process aimed at evaluating the potential environmental effects of pharmaceutical manufacturing, use, and disposal. It seeks to identify risks to ecosystems, water and air quality, and public health associated with pharmaceutical activities, ensuring responsible development and encouraging sustainable practices within the industry.
Key Features
- Systematic evaluation of environmental risks posed by pharmaceuticals
- Assessment of manufacturing processes, supply chains, and disposal methods
- Integration of environmental considerations into regulatory decision-making
- Promotion of sustainable and eco-friendly pharmaceutical production
- Use of scientific data, modeling, and monitoring to inform decisions
Pros
- Enhances understanding of pharmaceuticals' environmental impact
- Helps promote greener manufacturing practices
- Increases industry accountability and regulatory compliance
- Protects ecosystems and public health in the long term
Cons
- Can be resource-intensive and costly to implement
- Potential lack of standardized frameworks across jurisdictions
- May cause delays in product approvals or market entry
- Data gaps can limit assessment accuracy